Publications:69
Umut Ozbek, PhD
About Me
Dr. Özbek’s primary focus is on statistical genetics and genetic epidemiology. Her other interests include cancer clinical trials, longitudinal multivariate modelling, penalized regression methods, high-dimensional data analysis, and pharmacogenomics. Dr. Özbek has an extensive consulting experience in designing and analyzing clinical and experimental trials.
Language
English
Position
ASSOCIATE PROFESSOR | Population Health Science and Policy, ASSOCIATE PROFESSOR | Graduate Education
Education
BS, Middle East Technical University
MS, Ankara University
PhD, University of Pittsburgh
Publications
Selected Publications
- Emotional and Financial Stressors in New York City During the COVID-19 Pandemic: A Consecutive Cross-Sectional Analysis. David J. Heller, Devin Madden, Timnit Berhane, Nina A. Bickell, Grace Van Hyfte, Sarah Miller, Umut Ozbek, Jung Yi Lin, Rebecca M. Schwartz, Robert A. Lopez, Guedy Arniella, Victoria Mayer, Carol R. Horowitz, Emma K. Benn, Nita Vangeepuram. Journal of racial and ethnic health disparities
- A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study. Patrick Neven, Nicole Stahl, Maria Vidal, Miguel Martín, Peter A. Kaufman, Nadia Harbeck, Kelly K. Hunt, Stacey Carter, Francois Clement Bidard, Peter A. Fasching, Philippe Aftimos, Duncan Wheatley, Erika Hamilton, Rebecca Aft, Swati Kulkarni, Peter Schmid, Manali Bhave, Roohi Ismail-Khan, Claudia Karacsonyi, Shawn T. Estrem, Bastien Nguyen, Umut Ozbek, Eunice Yuen, Vanessa Rodrik-Outmezguine, Eva Ciruelos. Clinical Cancer Research
- Multi-scale signaling and tumor evolution in high-grade gliomas. Jingxian Liu, Song Cao, Kathleen J. Imbach, Marina A. Gritsenko, Tung Shing M. Lih, Jennifer E. Kyle, Tomer M. Yaron-Barir, Zev A. Binder, Yize Li, Ilya Strunilin, Yi Ting Wang, Chia Feng Tsai, Weiping Ma, Lijun Chen, Natalie M. Clark, Andrew Shinkle, Nataly Naser Al Deen, Wagma Caravan, Andrew Houston, Faria Anjum Simin, Matthew A. Wyczalkowski, Liang Bo Wang, Erik Storrs, Siqi Chen, Ritvik Illindala, Yuping D. Li, Reyka G. Jayasinghe, Dmitry Rykunov, Sandra L. Cottingham, Rosalie K. Chu, Karl K. Weitz, Ronald J. Moore, Tyler Sagendorf, Vladislav A. Petyuk, Michael Nestor, Lisa M. Bramer, Kelly G. Stratton, Athena A. Schepmoes, Sneha P. Couvillion, Josie Eder, Young Mo Kim, Yuqian Gao, Pei Wang, Shrabanti Chowdhury, Zeynep Gumus, Lyndon Kim, Umut Ozbek, Francesca Petralia, Boris Reva, Eric E. Schadt. Cancer Cell
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Ozbek during 2025 and/or 2026. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)
- Eli Lilly And Company
Outside Employment
- Eli Lilly And Company
Mount Sinai’s faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.